Carole Ben-Maimon, M.D. is the President and CEO of Larimar Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases. With a solid educational background, she earned her B.S. from the University of Pennsylvania and her M.D. from Jefferson...

Carole Ben-Maimon, M.D. is the President and CEO of Larimar Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases. With a solid educational background, she earned her B.S. from the University of Pennsylvania and her M.D. from Jefferson Medical College. Dr. Ben-Maimon has a rich experience in the pharmaceutical industry, holding leadership roles in several companies. Before joining Larimar in May 2020, she served as the CEO of Chondrial Therapeutics and was involved in strategic roles at companies like Impax Laboratories and Teva Pharmaceuticals. During her time at Larimar, she has played a crucial role in steering the company towards its goals, ensuring it remains at the forefront of biopharmaceutical innovation. In 2023, her total compensation was reported at $865,999, which reflects her performance-based bonus structure linked to corporate achievements. Besides her leadership position, Dr. Ben-Maimon's experience gives her a comprehensive view of the biopharmaceutical landscape, making her a significant figure in driving forward Larimar's mission to address unmet medical needs.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Larimar Therapeutics CEOs

L

Carole Ben-Maimon, M.D.

CEO of Larimar Therapeutics

Education

B.S. from the University of Pennsylvania; M.D. from Jefferson Medical College.

Sector of Economy

Healthcare

Born

January 1, 1961 - 64 years ago

CEO of Larimar Therapeutics for

5 years 2 months (May 2020 - Present)

Previous Experience

President and CEO of Chondrial Therapeutics, Inc.; President of Global Pharmaceuticals at Impax Laboratories; various roles in Barr Pharmaceuticals and Teva Pharmaceutical Industries.

Rivals

Competitors/colleagues of Carole Ben-Maimon, M.D.

Holdings

See how much did Carole Ben-Maimon, M.D. make over time.

As the CEO of Larimar Therapeutics, Carole Ben-Maimon, M.D. has been closely involved with the company's stock performance. In 2023, she received no stock grants and had no vested stock options, indicating a focus on cash compensation instead. Her total...

As the CEO of Larimar Therapeutics, Carole Ben-Maimon, M.D. has been closely involved with the company's stock performance. In 2023, she received no stock grants and had no vested stock options, indicating a focus on cash compensation instead. Her total compensation for the year was $865,999, combining a salary of $560,000, a bonus of $288,400, and other benefits. Over time, the fluctuation in her compensation reflects both her contributions and the ongoing performance of the company. Given her significant role since May 2020 and previous executive positions, Dr. Ben-Maimon’s financial stake and leadership decisions are closely watched by investors as they navigate the competitive biopharmaceutical landscape.

Loading...

Insider Trading

See recent insider trades of Carole Ben-Maimon, M.D..

No insider trades found for this CEO.

Compensation History

See how much did Carole Ben-Maimon, M.D. make over time.

In 2023, Carole Ben-Maimon, M.D. received total compensation of $865,999, comprised of a base salary of $560,000 and a performance-related bonus of $288,400 reflecting a slight increase from the prior year. Notably, her bonus was based on company performance and individual objectives, showcasing a pay-for-performance alignment. She has consistently focused on cash rather than stock options, with zero vested stocks reported in recent years. The structured bonus system and solid salary ensure she remains motivated and aligned with Larimar’s growth and innovations in the biopharmaceutical field. Since she joined the company in 2020, her compensation has mirrored the company’s changing dynamics and market conditions, which are vital for shareholders to consider.

Year

2023

Total Compensation

$865.00K

Salary

$560.00K

Board Justification

Our executive compensation program is designed to attract, motivate and retain our named executive officers who are critical to our success, aligning with our pay-for-performance philosophy.

Bonus

$288.40K

Board Justification

Represents bonus paid in February 2024 based upon 2023 corporate performance, as approved by our Compensation Committee or Board, as applicable.

Other

$16.60K

Board Justification

Includes the Company’s contribution to a 401(k) plan and the value of group term life benefits provided by the Company.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The 2023 annual bonuses for Dr. Ben-Maimon were targeted at 50% of her base salary, with an overall achievement level of 103%.

Other Larimar Therapeutics CEOs

Here are other CEOs of Larimar Therapeutics

Jeffrey S. Hatfield

Ex-CEO of Larimar Therapeutics

October 2017 - May 2020